Research programme: peripherally acting cannabinoid receptor CB1 antagonists - Jenrin Discovery

Drug Profile

Research programme: peripherally acting cannabinoid receptor CB1 antagonists - Jenrin Discovery

Alternative Names: JD-2000 series; JD-2114; JD-5000 series; JD-5006; JD-5037; JD-6000 series

Latest Information Update: 22 Dec 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Jenrin Discovery
  • Developer Jenrin Discovery; National Institutes of Health (USA)
  • Class Small molecules
  • Mechanism of Action Cannabinoid 1 receptor inverse agonists; Cannabinoid receptor CB1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Atherosclerosis; Diabetes mellitus; Hyperlipidaemia; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Obesity

Most Recent Events

  • 14 Dec 2017 Prior to December 2017, preclinical trials in Non-alcoholic steatohepatitis in USA
  • 14 Dec 2017 US FDA approves IND application for JD 5037 in Non-alcoholic steatohepatitis
  • 14 Dec 2017 Jenrin Discovery plans to initiate a phase I trial for Non-alcoholic steatohepatitis in USA ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top